Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brande Thomas-Fowlkes

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
SLAS Technology|February 1, 2020
Cell-Based In Vitro Assay Automation: Balancing Technology and Data Reproducibility/PredictabilityBrande Thomas-Fowlkes, Steven Cifelli, Sarah Souza, et al.
Plos One|May 26, 2017
GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose productionCorin Miller, Michele J Pachanski, Melissa E Kirkland, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2013
Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresisMaria L Garcia, Birgit T Priest, Magdalena Alonso-Galicia, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2016
The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II PhenotypeCaryn Hampton, Xiaoyan Zhou, Birgit T Priest, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2013
Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-oneHaifeng Tang, Reynald K de Jesus, Shawn P Walsh, et al.
Bioorganic & Medicinal Chemistry Letters|March 28, 2016
Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporationShawn P Walsh, Aurash Shahripour, Haifeng Tang, et al.
Journal of Medicinal Chemistry|May 26, 2021
Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/NatriureticJinlong Jiang, Fa-Xiang Ding, Xiaoyan Zhou, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart FailureHaifeng Tang, Yuping Zhu, Nardos Teumelsan, et al.
Bioorganic & Medicinal Chemistry Letters|April 23, 2017
Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophoresShuzhi Dong, Kelsey VanGelder, Zhi-Cai Shi, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMsHelen Y Chen, Christopher W Plummer, Dong Xiao, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
SLAS Technology|February 1, 2020
Cell-Based In Vitro Assay Automation: Balancing Technology and Data Reproducibility/PredictabilityBrande Thomas-Fowlkes, Steven Cifelli, Sarah Souza, et al.
Plos One|May 26, 2017
GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose productionCorin Miller, Michele J Pachanski, Melissa E Kirkland, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2013
Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresisMaria L Garcia, Birgit T Priest, Magdalena Alonso-Galicia, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2016
The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II PhenotypeCaryn Hampton, Xiaoyan Zhou, Birgit T Priest, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2013
Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-oneHaifeng Tang, Reynald K de Jesus, Shawn P Walsh, et al.
Bioorganic & Medicinal Chemistry Letters|March 28, 2016
Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporationShawn P Walsh, Aurash Shahripour, Haifeng Tang, et al.
Journal of Medicinal Chemistry|May 26, 2021
Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/NatriureticJinlong Jiang, Fa-Xiang Ding, Xiaoyan Zhou, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart FailureHaifeng Tang, Yuping Zhu, Nardos Teumelsan, et al.
Bioorganic & Medicinal Chemistry Letters|April 23, 2017
Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophoresShuzhi Dong, Kelsey VanGelder, Zhi-Cai Shi, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMsHelen Y Chen, Christopher W Plummer, Dong Xiao, et al.
Pageof 2